EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Marfan Syndrome versus Loeys–Dietz Syndrome after Aortic Surgery: A Systematic Review and Meta-analysis of Reconstructed Time-to-Event Data

Johannes Fischer, Steve Wehner, Ayodeji Arobo, Abdullah Almehandi, Felipe S. Passos, Christian Eitel, Hristo Kirov, Xander Jacquemyn, Ibrahim Sultan, Torsten Doenst, Tulio Caldonazo

AORTA · 2026-10-08 · 14 (CP)

DOI: 10.1055/a-2965-6400 ↗
AbstractBibliografische Angaben

Abstract

Abstract Marfan syndrome (MFS) and Loeys–Dietz syndrome (LDS) are hereditary connective tissue diseases, both characterized by aortic root and vessel involvement with an increased risk of aneurysms and dissections. Despite advances in surgical techniques and improved postoperative follow-up, the impact of surgery on long-term outcomes in these patient groups is still unknown. We performed a systematic review and a meta-analysis to compare the postoperative long-term events. The main outcome was long-term survival. Additional outcomes were freedom from dissection and reoperation. After reconstruction of time-to-event data for the individual survival analysis, pooled Kaplan–Meier curves for the endpoints were generated. A total of 1,794 studies were identified, of which 5 were included in the analysis, encompassing 1,005 patients (MFS: 778; LDS: 227). With MFS as the reference group, there was no significant difference in long-term survival between both groups, based on age (hazard ratio [HR]: 0.919; 95% confidence interval [CI]: 0.58–1.45; p=0.717) or postoperative follow-up (HR: 0.997; 95% CI: 0.45–2.19; p=0.995). However, LDS was associated with higher risk of dissection (HR: 0.331; 95% CI: 0.21–0.53; p

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →